large and 4 small ring chromosomes 8. One MYC signal was deleted from one of the 2 chromosomes 8. FISH with a FUS probe at 16p11.2 showed monoallelic deletion of FUS . Immunohistochemistry demonstrated MYC protein overexpression at diagnosis and almost negative expression in CR. These results indicate that MYC amplification could occur in ring chromosomes without dmin. A cryptic MYC deletion suggests that an episome model could be applicable to MYC amplification in ring chromosomes as observed for dmin and hsr. Furthermore, considering 2 further reported cases, t(11; 16)(q13;p11) may be a very rare but recurrent translocation in AML.
MYC
. These aberrations are usually detected as part of a complex karyotype and are associated with chemotherapy resistance, disease progression, and poor prognosis. In addition to dmin and hsr, KMT2A amplification was reported to have variable cytogenetic manifestations including ring chromosomes, marker chromosomes, and other forms of structurally rearranged chromosomes [Streubel et al., 2000; Dolan et al., 2002] . On the other hand, MYC amplification in ring and marker chromosomes appears to be a very rare event because only a few cases of MDS/AML with this abnormality have been characterized [Reddy, 2007; Xiang et al., 2015] . Chromosomal aberrations involving the short arm of chromosome 16 are often observed in hematological malignancies. They frequently include 16p13 as a major breakpoint such as inv(16)(p13q22) in AML M4Eo in the French-American-British classification. As recurrent translocations involving 16p11, t(3; 16)(q27;p11) and t(16; 21)(p11;q22) have been analyzed in diffuse large Bcell lymphoma and AML, respectively [Ueda et al., 2002; Dessen and Huret, 2017] . The latter translocation leads to a fusion gene between FUS at 16p11.2 and ERG at 21q22 and seems to correlate with the M2/M5 subtype and poor prognosis [Kong et al., 1997] . However, other translocations including 16p11 have rarely been reported. Here, we describe a unique case of AML with MYC amplification in ring chromosomes 8 that were associated with a novel recurrent translocation t(11; 16)(q13;p11.2).
Case Report and Results
A 62-year-old woman was admitted to our hospital due to anemia and thrombocytopenia. She had no history of chemoradiotherapy or cytopenia prior to diagnosis of AML. On admission, peripheral blood values were as follows: hemoglobin 78 g/L, platelets 68 × 10 9 /L, and leukocytes 9.3 × 10 9 /L with 25% blasts, 1% metamyelocytes, 2% band forms, 20% segmented neutrophils, 4% eosinophils, 5% basophils, 17% monocytes, and 26% lymphocytes. Her bone marrow was hypercellular with 78.6% blasts, 5.8% other myeloid cells, 3.2% eosinophils, 0.4% basophils, 4.2% monocytes, 1.8% lymphocytes, and 6.0% erythroblasts. Blasts had fine nuclear chromatin, nucleoli, and basophilic cytoplasm and were positive and negative for myeloperoxidase staining and double esterase staining, respectively. Some of them had intracytoplasmic micronuclei or Auer rods ( Fig. 1 A, B) . Dysplastic changes of other bone marrow cells were not apparent.
The bone marrow clot section showed hypercellular marrow with diffusely infiltrated blasts that were immunohistochemically positive for myeloperoxidase and CD117 and negative for TdT and CD34 ( Fig. 1 C) . Immunophenotyping by 3-color flow cytometry using CD45/ side-scatter gating revealed that the gated cells were positive (>20%) for CD7 (28.2%), CD13 (66.8%), CD33 (99.4%), and HLA-DR (69.1%) but negative for CD34 (13.9%) and other lymphoid markers. On the basis of these analyses a diagnosis of de novo AML M2 in the French-American-British classification or AML, not otherwise specified (AML with maturation) in the World Health Organization classification was made. The patient received induction therapy with idarubicin and cytarabine according to the JALSG AML201 protocol [Ohtake et al., 2011] and achieved complete remission (CR). She then received a further 4 courses of conventional consolidation therapy and remains in hematological and cytogenetic CR for more than 30 months. Chromosome analysis of bone marrow cells at the initial diagnosis showed 51,XX,t(11; 16)(q13;p11.2),+r1, +mar1×4[3]/50,sl,-X[6]/46,XX [4] ( Fig. 2 A) . At the hematological CR after induction therapy, the karyotype returned to 46,XX [20] . Spectral karyotyping confirmed the occurrence of der(11)t(11; 16)(q13;p11.2) and der(16) t(11; 16)(q13;p11.2) and revealed that the ring chromosome was derived from chromosome 8 ( Fig. 2 B) . The analysis also showed that the marker chromosome was another small ring chromosome 8. To analyze the possible association between MYC at 8q24 and these ring chromosomes 8, we performed FISH with an IGH/MYC / CEP8 probe. Amplified MYC signals were detected at similar intensities on 1 large and 4 small ring chromosomes 8 in 17 of 20 metaphase spreads ( Fig. 3 A) . Interestingly, 1 MYC signal was deleted from one of the 2 chromosomes 8. FISH on interphase nuclei also detected clusters of amplified MYC signals in 98 of 100 cells. We next carried out FISH with the FUS probe at 16p11.2 to examine whether FUS was involved in the t(11; 16)(q13;p11.2) translocation. Unexpectedly, 1 FUS signal was deleted, indicating that FUS was not rearranged and the 16p11.2 breakpoint was centromeric to FUS ( Fig. 3 B) . We also performed FISH with a CCND1 probe at 11q13 and found that this gene was translocated to the der(16)t(11; 16) (q13;p11.2). Therefore, the 11q13 breakpoint was centromeric to CCND1 (data not shown).
As MYC gene amplification often results in increased MYC protein expression [Huh et al., 2016] , we performed immunohistochemical staining on the bone marrow clot section for this protein. At the initial diagnosis of AML, about 80% of bone marrow cells were highly positive for MYC protein expression ( Fig. 1 D) , whereas at CR this protein could only be detected in a few cells ( Fig. 1 E) .
Discussion
MYC amplification in ring chromosomes 8, MYC protein overexpression, and t(11; 16)(q13;p11.2) with a cryptic deletion of FUS were detected in a patient with de novo AML M2. Morphologically, both intracytoplasmic micronuclei and Auer rods were observed in myeloblasts. Micronuclei are defined as small nuclear-like structures, and they usually contain amplified oncogenes or acentric chromosome fragments. It has recently been shown that micronuclei are closely correlated with oncogene amplification in the form of dmin in MDS/AML [Huh et al., 2016] . Interestingly, our results demonstrated that micronuclei could also be observed within leukemic blasts containing MYC amplification in ring chromosomes, even if these cells did not present dmin.
To the best of our knowledge, only 4 cases of MDS/ AML with MYC amplification in ring chromosomes or ring-like marker chromosomes have been reported (cases 3 to 6 in Table 1 ). Therefore, MYC amplification in ring/ marker chromosomes may be a very rare genetic event in MDS/AML. In case 3, variable dmin were detected at the diagnosis of refractory anemia with excess blasts (RAEB). During progression to RAEB in transformation, 2 distinct ring-like marker chromosomes appeared as a new abnormal clone [Reddy, 2007] . Because both dmin and markers were MYC -positive, the author suggested that the ringlike markers contained hsr with amplified copies of MYC . Dmin as an earlier event may have evolved to form hsr.
Similarly, case 4 had various clones with MYC amplification: 2 contained different ring chromosomes and 1 had dmin [Rayeroux and Campbell, 2009] . In case 5, high-resolution oligonucleotide array detected MYC amplification. In addition to marker chromosomes, the presence of dmin was demonstrated by metaphase FISH [Chinen et al., 2014] . In contrast, case 6 showed MYC amplification in marker chromosomes and EZH2 microdeletion [Xiang et al., 2015] . There were 3-5 marker chromosomes but no dmin in that abnormal clone. Moreover, in the present case, we could not detect dmin in metaphase spreads. Together with case 6, our results indicate that MYC amplification can occur in the ring/marker chromosomes without dmin. As was previously suggested, it might be possible that the ring/marker chromo- somes contained hsr formed by amplified MYC signals [Reddy, 2007] . Importantly, FISH on metaphase spreads revealed that 1 MYC signal was deleted from one of the 2 chromosomes 8. A cryptic MYC deletion in one chromosome 8 homologue has previously been shown in MDS/AML with MYC -containing dmin [Storlazzi et al., 2006] . This type of gene amplification mechanism follows the "episome model". Here, DNA segments containing MYC are excised from chromosome 8, circularized, and amplified by mutual recombination to either produce dmin or become integrated into chromosomes to generate hsr. Similar cryptic MYC deletions were also detected in cases 3 and 6. Therefore, these findings confirmed that an episome model could be applicable to MYC amplification in ring/ marker chromosomes as observed in dmin and hsr. Storlazzi et al. [2006] also showed a low expression of MYC but overexpression of TRIB1 by Northern blot analyses, suggesting that MYC is not the target gene of 8q24 amplifications. However, it was recently reported that MYC protein expression was observed in all cases of MDS/ AML with dmin [Huh et al., 2016] . We also demonstrated MYC protein overexpression at the diagnosis of AML and almost negative expression in hematological and cytogenetic CR. The MYC protein plays a pivotal role in regulating normal hematopoiesis, and its deregulation may transform hematopoietic cells by stimulating proliferation and blocking differentiation [Delgado et al., 2013] . Our results clearly indicate that MYC protein expression correlates with MYC gene amplification during the clinical course, and suggest that they play a crucial role in leukemogenesis.
In addition to MYC amplification, the present case had a reciprocal translocation t(11; 16)(q13;p11.2). As shown in Table 1 , only 2 cases of human malignancies with t(11; 16)(q13;p11) have previously been reported in the literature: one with AML M4 and the other with AML M2 (cases 1 and 2) [Mitelman et al., 2017] . Thus, t(11; 16)(q13;p11) may be a very rare novel recurrent translocation in AML. Common clinical and genetic features could not be found because only limited data were available. Case 1 showed t(11; 16)(q13;p11) as a sole abnormality, indicating that this translocation could be a primary genetic event [Lemež et al., 2000] . In contrast, case 2 had t(8; 21)(q22;q22) which is one of the most common genetic abnormalities in AML. In consequence, t(11; 16) was supposed to be a secondary aberration [Hilgenfeld et al., 2001] . Both these translocations did not involve a gain or loss of material of these chromosomes. At present, there is no evidence that the t(11; 16) may be active in causing AML. Thus, in the present case, MYC amplification in ring chromosomes 8 might be a primary cause for AML, because the pathological significance of MYC amplification has been demonstrated by other reports [Thomas et al., 2004; Storlazzi et al., 2006; Huh et al., 2016] .
FISH with the FUS probe revealed a cryptic deletion of FUS in association with t(11; 16)(q13;p11.2). The FUS gene encodes an RNA-binding protein known to form a FUS/ERG fusion gene in AML with t(16; 21)(p11;q22) [Kong et al., 1997] . A few mutations/deletions in FUS were associated with juvenile-onset amyotrophic lateral sclerosis [Belzil et al., 2012] . However, to our knowledge, FUS deletion has not previously been described in hematological malignancies. Cryptic deletions in balanced translocations seem to be rare in hematological malignancies: a similar cryptic deletion of EGR1 at 5q31 in association with t(5; 22)(q31;q11.2) was previously described in a patient with MDS [Hoffman et al., 2009] . At present, the clinical significance of cryptic FUS deletion in leukemogenesis is unclear.
FISH clarified that the 11q13 and 16p11.2 breakpoints of the present case were centromeric to CCND1 and to FUS , respectively. As a recurrent aberration involving 11q13 or 16p11.2, except for that with CCND1 or FUS , t(11; 21)(q13;q22) leading to RUNX1/MACROD1 was reported in AML [Imagama et al., 2007; Dessen and Huret, 2012a] . In addition to MACROD1 , the 11q13 region centromeric to CCND1 contains several tumor-related genes, such as EHD1 involved in diffuse large B-cell lymphoma with t(11; 14)(q13;q24), and RELA in acute erythroleukemia with t(11; 20)(q13;q13) [Morin et al., 2013; Panagopoulos et al., 2013] . In contrast, the 16p11.2 region centromeric to FUS contains ZNF267 , ITGAX , and ARMC5 that are involved in bladder transitional cell carcinoma with t(1; 16)(p33;p11), bladder transitional cell carcinoma with t(16; 16)(p11;p11), and breast adenocarcinoma with t(8; 16)(p11;p11), respectively [Dessen and Huret, 2012b; Yoshihara et al., 2015] . It is possible that these genes located at 11q13 or 16p11.2 formed a novel fusion gene implicated in the pathogenesis of AML by t(11; 16)(q13;p11.2). Identification of genes in both breakpoints will be beneficial to elucidate the pathological role of t(11; 16)(q13; p11.2) and possible synergistic effects with MYC amplification in AML.
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